Insider Trading Alert - PETS, GEVO And TASR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 11, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,570.00 to $275,612,220.00.

Highlighted Stocks Traded by Insiders:

PetMed Express (PETS) - FREE Research Report

Formica Frank J, who is Director at PetMed Express, sold 7,500 shares at $16.51 on May 11, 2015. Following this transaction, the Director owned 46,000 shares meaning that the stake was reduced by 14.02% with the 7,500-share transaction.

The shares most recently traded at $16.11, down $0.40, or 2.48% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 21,070
  • 12-Week # shares sold: 47,070
  • 24-Week # shares sold: 109,737

The average volume for PetMed Express has been 197,900 shares per day over the past 30 days. PetMed Express has a market cap of $334.3 million and is part of the health care sector and drugs industry. Shares are up 14.82% year-to-date as of the close of trading on Monday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.36%. The company has a P/E ratio of 19.0. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gevo (GEVO) - FREE Research Report

Gruber Patrick R., who is Chief Executive Officer at Gevo, sold 1,432 shares at $4.50 on May 11, 2015. Following this transaction, the Chief Executive Officer owned 19,225 shares meaning that the stake was reduced by 6.93% with the 1,432-share transaction.

The shares most recently traded at $2.78, down $1.72, or 61.87% since the insider transaction. Historical insider transactions for Gevo go as follows:

  • 4-Week # shares bought: 181,484
  • 4-Week # shares sold: 9,447
  • 12-Week # shares bought: 181,484
  • 12-Week # shares sold: 41,121
  • 24-Week # shares bought: 181,484
  • 24-Week # shares sold: 90,811

The average volume for Gevo has been 326,100 shares per day over the past 30 days. Gevo has a market cap of $23.6 million and is part of the basic materials sector and chemicals industry. Shares are down 58.12% year-to-date as of the close of trading on Tuesday.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The company operates in two segments, Gevo, Inc.; and Gevo Development/Agri-Energy. Currently, there are 2 analysts who rate Gevo a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GEVO - FREE

TheStreet Quant Ratings rates Gevo as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself. Get the full Gevo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Taser International (TASR) - FREE Research Report

Klint Douglas E, who is General Counsel at Taser International, sold 21,961 shares at $32.79 on May 11, 2015. Following this transaction, the General Counsel owned 55,577 shares meaning that the stake was reduced by 28.32% with the 21,961-share transaction.

The shares most recently traded at $33.62, up $0.83, or 2.47% since the insider transaction. Historical insider transactions for Taser International go as follows:

  • 4-Week # shares sold: 13,866
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 13,866
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 16,216

The average volume for Taser International has been 2.4 million shares per day over the past 30 days. Taser International has a market cap of $1.7 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 20.62% year-to-date as of the close of trading on Monday.

TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The company has a P/E ratio of 86.3. Currently, there are 2 analysts who rate Taser International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TASR - FREE

TheStreet Quant Ratings rates Taser International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Taser International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Meet TheStreet's Pets! They May Be Expensive -- But We Love Them!

Meet TheStreet's Pets! They May Be Expensive -- But We Love Them!

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round